Get started
Author

Ella L. Kim

Observed names: E Kim, E L Kim, E. Kim, E. L. Kim, E.L. Kim, EL Kim, Ella Kim, Ella L Kim, Kim E, Kim, E, Kim, E., Kim, Ella, Kim, Ella L, Kim, Ella L.
Observed institutions: Brigham and Women's Hospital, Barrow Neurological Institute, Harvard University, Leibniz Institute of Virology (LIV), Children's Medical Research Institute, Universität Hamburg, Johannes Gutenberg University Mainz, University of California San Diego, University Medical Center of the Johannes Gutenberg University Mainz, University Medical Center Hamburg-Eppendorf, Universitätsmedizin Göttingen, Paracelsus Elena Klinik Kassel, Moores Cancer Center, Institute of Molecular Biology and Genetics, University of Göttingen, University of Lübeck
OpenAlex ID: A5019233746
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity
2012 · N. M. Teplyuk, B. Mollenhauer, et al. · Neuro-Oncology · 302
Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53
1999 · Nils Albrechtsen, Irene Dornreiter, et al. · Oncogene · 182
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells
2010 · E. L. Kim, R. Wustenberg, et al. · Neuro-Oncology · 149
PDF
In vivo multiphoton tomography and fluorescence lifetime imaging of human brain tumor tissue
2016 · Sven R. Kantelhardt, Darius Kalasauskas, et al. · Journal of Neuro-Oncology · 103
Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs
2018 · Anton Buzdin, Maxim Sorokin, et al. · Seminars in Cancer Biology · 102
Transcriptional activities of mutant p53: When mutations are more than a loss
2004 · Ella Kim, Wolfgang Deppert · Journal of Cellular Biochemistry · 102
PDF
RNA sequencing for research and diagnostics in clinical oncology
2019 · Anton Buzdin, Maxim Sorokin, et al. · Seminars in Cancer Biology · 93
Wild-type p53 in cancer cells: When a guardian turns into a blackguard
2008 · Ella Kim, Alf Giese, et al. · Biochemical Pharmacology · 82
Specific Interaction of p53 with Target Binding Sites Is Determined by DNA Conformation and Is Regulated by the C-terminal Domain
2002 · Thomas Göhler, Maurice Reimann, et al. · Journal of Biological Chemistry · 80
PDF
Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables
2018 · Patrick Weyerhäuser, Sven R. Kantelhardt, et al. · Frontiers in Oncology · 77
PDF
Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase
2016 · Juliya Kalinina, Jun Ahn, et al. · Clinical Cancer Research · 72
Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization
2005 · Sven Hanson, Ella Kim, et al. · Oncogene · 70
Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma
2020 · Ella L. Kim, Maxim Sorokin, et al. · Cancers · 62
PDF
The complex interactions of p53 with target DNA: we learn as we go
2003 · Ella Kim, Wolfgang Deppert · Biochemistry and Cell Biology · 62
DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53
1997 · Ella Kim, Nils Albrechtsen, et al. · Oncogene · 62
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression
2022 · Daniela Hanisch, Andrea Krumm, et al. · Cell Death and Disease · 59
PDF
Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment
2014 · Mirjam Renovanz, Ella L. Kim · Frontiers in Oncology · 54
PDF
Thromboxane synthase regulates the migratory phenotype of human glioma cells
1999 · Alf Giese, Christian Hagel, et al. · Neuro-Oncology · 54
PDF
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
2016 · Nancy Berte, Stefanie Lokan, et al. · Oncotarget · 50
PDF
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1
2003 · Ella Kim, Willy Günther, et al. · Oncogene · 50
Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53
1999 · Ella Kim, Gabor Rohaly, et al. · Oncogene · 50
CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells
2015 · Alonso Barrantes-Freer, Mirjam Renovanz, et al. · PLoS ONE · 46
PDF
Mutant p53: ?gain of function? through perturbation of nuclear structure and function?
2000 · Wolfgang Deppert, Thomas G�hler, et al. · Journal of Cellular Biochemistry · 46
The versatile interactions of p53 with DNA: when flexibility serves specificity
2006 · E Kim, W Deppert · Cell Death and Differentiation · 44
Interactions of mutant p53 with DNA: guilt by association
2007 · E Kim, W Deppert · Oncogene · 42
Works count: 141
Citation count: 2,631
H-index: 29
I10-index: 50
Year
Topic
Type